Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Leases: 2019-2025

Historic Operating Leases for Arrowhead Pharmaceuticals (ARWR) over the last 6 years, with Sep 2025 value amounting to $111.4 million.

  • Arrowhead Pharmaceuticals' Operating Leases rose 0.34% to $111.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.4 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $111.4 million for FY2025, which is 0.34% up from last year.
  • Arrowhead Pharmaceuticals' Operating Leases amounted to $111.4 million in Q3 2025, which was down 1.15% from $112.7 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Operating Leases registered a high of $118.9 million during Q1 2024, and its lowest value of $22.5 million during Q4 2021.
  • Moreover, its 3-year median value for Operating Leases was $112.7 million (2025), whereas its average is $108.3 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Operating Leases surged by 265.22% in 2022, and later fell by 4.57% in 2025.
  • Arrowhead Pharmaceuticals' Operating Leases (Quarterly) stood at $22.5 million in 2021, then spiked by 265.22% to $82.1 million in 2022, then skyrocketed by 44.37% to $118.6 million in 2023, then decreased by 2.30% to $115.9 million in 2024, then climbed by 0.34% to $111.4 million in 2025.
  • Its Operating Leases stands at $111.4 million for Q3 2025, versus $112.7 million for Q2 2025 and $114.3 million for Q1 2025.